US 12,226,572 B2
Systems and methods for delivery of therapeutic gas
Jaron M. Acker, Madison, WI (US); Jeff Milsap, Cambridge, WI (US); Robin Roehl, Janesville, WI (US); Jeffrey Schmidt, Fitchburg, WI (US); and Craig R. Tolmie, Stoughton, WI (US)
Assigned to Mallinckrodt Pharmaceuticals Ireland Limited, Dublin (IE)
Filed by Mallinckrodt Pharmaceuticals Ireland Limited, Dublin (IE)
Filed on Nov. 10, 2022, as Appl. No. 17/984,893.
Application 17/984,893 is a continuation of application No. 16/748,319, filed on Jan. 21, 2020, granted, now 11,529,479.
Application 16/748,319 is a continuation of application No. 14/709,316, filed on May 11, 2015, granted, now 10,576,225, issued on Mar. 3, 2020.
Claims priority of provisional application 61/991,028, filed on May 9, 2014.
Claims priority of provisional application 61/991,083, filed on May 9, 2014.
Claims priority of provisional application 61/991,032, filed on May 9, 2014.
Prior Publication US 2023/0073254 A1, Mar. 9, 2023
Int. Cl. A61M 16/00 (2006.01); A61M 16/10 (2006.01); A61M 16/12 (2006.01); A61M 16/20 (2006.01); B63C 11/02 (2006.01); G01F 22/02 (2006.01); A61M 16/08 (2006.01)
CPC A61M 16/0051 (2013.01) [A61M 16/024 (2017.08); A61M 16/1005 (2014.02); A61M 16/12 (2013.01); A61M 16/122 (2014.02); A61M 16/125 (2014.02); A61M 16/201 (2014.02); A61M 16/202 (2014.02); A61M 16/204 (2014.02); B63C 11/02 (2013.01); G01F 22/02 (2013.01); A61M 2016/0027 (2013.01); A61M 2016/0039 (2013.01); A61M 16/085 (2014.02); A61M 2016/102 (2013.01); A61M 16/208 (2013.01); A61M 2202/0275 (2013.01); A61M 2205/14 (2013.01); A61M 2205/16 (2013.01); A61M 2205/17 (2013.01); A61M 2205/3331 (2013.01); A61M 2205/3334 (2013.01); A61M 2205/3368 (2013.01); A61M 2205/3379 (2013.01); A61M 2205/50 (2013.01); A61M 2205/502 (2013.01); A61M 2205/52 (2013.01); A61M 2205/60 (2013.01); A61M 2205/6018 (2013.01); A61M 2205/6072 (2013.01); A61M 2205/8206 (2013.01); F17C 2250/00 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method of providing therapeutic gas from a secondary delivery subsystem, comprising:
detecting a problem with a primary gas delivery system configured to deliver a therapeutic gas flow;
automatically switching therapeutic gas flow control to a flow control channel of the secondary delivery subsystem, wherein the flow control channel is operable to receive the therapeutic gas flow and is in fluid communication with a secondary shut off valve, a secondary flow control valve, a secondary delivery flow sensor, and a secondary confirmatory flow sensor; and
switching a flow regulating valve to deliver the therapeutic gas to a primary outlet, a low pressure outlet, and an injector module, wherein the flow regulating valve is at a blending junction and is in fluid communication with the flow control channel.